Wojciech Krzysztof Grabowski

Mr. Wojciech Krzysztof Grabowski

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2024 in Quality in Sport
Verified
Journal Article
Open access
PDF file
WGWojciech Krzysztof Grabowski
Wojciech Krzysztof Grabowski
KKKarolina Anna Karoń
Karolina Anna Karoń
ŁKŁukasz Mikołaj Karoń
Łukasz Mikołaj Karoń
AZAnna Ewa Zygmunt
Anna Ewa Zygmunt
GDGrzegorz Drapała
Grzegorz Drapała
DPDaria Katarzyna Pedrycz
Daria Katarzyna Pedrycz
Ashwagandha (Withania somnifera) is known for its adaptogenic properties, helping the body manage stress from various sources. This review, based on 23 studies, evaluates Ashwagandha's effectiveness in enhancing sleep quality and reducing stress. The herb's bioactive compounds modulate stress responses and neurotransmitter systems, contributing to improved mental and physical resilience. The studies consistently show that Ashwagandha supplementation (250 to 600 mg daily for 4 to 12 weeks) significantly improves sleep quality, latency, and efficiency. These effects are largely due to the modulation of the hypothalamic-pituitary-adrenal (HPA) axis, cortisol reduction, and enhancement of GABAergic and serotonergic pathways. Ashwagandha also extends total sleep time in various populations, including healthy adults and the elderly. In addition to enhancing sleep, Ashwagandha reduces stress by lowering cortisol levels and modulating neurotransmitter systems. Numerous studies highlight its role in alleviating anxiety and improving mental well-being. However, some studies report gastrointestinal issues and potential interactions with medications, necessitating caution and consultation with healthcare providers. This review synthesizes current research, identifies trends, and highlights gaps in the literature, contributing to a better understanding of Ashwagandha's role in modern health practices. Given the challenges of sleep disorders and stress-related conditions, Ashwagandha shows promise as a natural remedy, particularly for those with anxiety or chronic stress. Future research should focus on understanding the underlying mechanisms, ensuring long-term safety, and standardizing supplement quality to strengthen its therapeutic applications.

17 November 2024 in Quality in Sport
Verified
Journal Article
Open access
PDF file
ŁKŁukasz Karoń
Łukasz Karoń
AZAnna Ewa Zygmunt
Anna Ewa Zygmunt
KKKarolina Karoń
Karolina Karoń
WGWojciech Krzysztof Grabowski
Wojciech Krzysztof Grabowski
GDGrzegorz Drapała
Grzegorz Drapała
DPDaria Pedrycz
Daria Pedrycz
L-arginine, a semi-essential amino acid, has garnered significant attention for its potential to enhance athletic performance, particularly within endurance sports. Recognized for its multifaceted roles in cardiovascular, immune, and metabolic functions, L-arginine serves as a precursor to biologically active molecules, including nitric oxide (NO), creatine, and polyamines, which are integral to muscle function and recovery. Through its ability to stimulate NO production, L-arginine promotes vasodilation, enhancing blood flow and oxygen delivery to active muscles, thereby improving exercise efficiency and endurance. Additionally, L-arginine influences muscle protein synthesis (MPS) via activation of the mTOR signaling pathway, aids in ammonia detoxification within the urea cycle, and supports cellular energetics by facilitating ATP production. These mechanisms collectively underscore its potential to support prolonged physical exertion, reduce muscle fatigue, and expedite post-exercise recovery. This systematic review examines current evidence on L-arginine supplementation in endurance athletes, focusing on its physiological impacts, mechanisms of action, and potential to enhance recovery and performance. Despite promising findings, variability in individual responses and mixed results across studies highlight the need for refined dosing strategies and further research into long-term safety and efficacy. This review provides a comprehensive overview of L-arginine's potential as a supplement in sports nutrition, aiming to inform evidence-based recommendations for its application in endurance training and recovery strategies.

26 October 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
ŁKŁukasz Mikołaj Karoń
Łukasz Mikołaj Karoń
AZAnna Zygmunt
Anna Zygmunt
KKKarolina Karoń
Karolina Karoń
WGWojciech Krzysztof Grabowski
Wojciech Krzysztof Grabowski
GDGrzegorz Drapała
Grzegorz Drapała
DPDaria Pedrycz
Daria Pedrycz
Epilepsy is a chronic neurological disorder characterized by a persistent tendency for the brain to generate seizures, affecting approximately 0.5–1% of the global population. Despite advances in pharmacological treatments and surgical interventions, around 30% of individuals with epilepsy continue to experience seizures, leading to significant impacts on quality of life. Among these individuals, many suffer from drug-resistant epilepsy (DRE), where seizures persist despite optimal drug therapy or surgical interventions.In recent years, the ketogenic diet (KD)—a high-fat, low-carbohydrate dietary regimen—has emerged as an effective non-pharmacological strategy for managing DRE. The KD works by inducing ketosis, a metabolic state where the body uses fat as the primary energy source instead of carbohydrates, which has been associated with neuroprotective effects and significant seizure reduction. Variants of the KD, such as the Modified Atkins Diet (MAD) and Low Glycemic Index Treatment (LGIT), offer less restrictive alternatives that have shown similar efficacy in reducing seizure frequency.This review explores the cellular and molecular mechanisms of the KD, evaluates its safety and tolerability across different age groups, and assesses its efficacy in treating epilepsy, particularly DRE. The findings underscore the potential of personalized dietary interventions to serve as effective adjunctive therapies in the management of epilepsy, offering new hope for individuals who do not respond to conventional treatments.

26 October 2024 in Quality in Sport
Verified
Journal Article
Open access
PDF file
AZAnna Ewa Zygmunt
Anna Ewa Zygmunt
ŁKŁukasz Karoń
Łukasz Karoń
KKKarolina Karoń
Karolina Karoń
WGWojciech Krzysztof Grabowski
Wojciech Krzysztof Grabowski
DPDaria Pedrycz
Daria Pedrycz
EPEmilia Pedrycz
Emilia Pedrycz
Echinacea, a widely used herbal remedy derived from the purple coneflower, is renowned for its potential benefits in treating and preventing the common cold. This review examines Echinacea’s role in managing cold symptoms, its mechanisms of action, and its efficacy across various species and preparations. Echinacea species, particularly Echinacea purpurea, Echinacea angustifolia, and Echinacea pallida, contain active compounds such as alkamides, caffeic acid derivatives, polysaccharides, and glycoproteins, which contribute to its immunomodulatory, anti-inflammatory, and antiviral properties. Clinical studies demonstrate that Echinacea can modestly reduce the incidence, duration, and severity of colds, though results are variable due to differences in preparation forms (e.g., teas, tinctures, extracts) and study methodologies. Proprietary extracts like Echinaforce® have shown consistent benefits, while other formulations have yielded mixed results. Despite a generally favorable safety profile, including mild gastrointestinal disturbances and rare allergic reactions, the long-term safety, particularly in vulnerable populations, remains under-researched. Future research should focus on standardized formulations, detailed molecular mechanisms, and rigorous clinical trials to better define Echinacea’s role in cold management. Overall, while Echinacea offers a promising option for cold prevention and treatment, its use should be informed by evidence-based practices considering formulation, dosage, and individual patient factors.

26 November 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
ŁKŁukasz Mikołaj Karoń
Łukasz Mikołaj Karoń
AZAnna Zygmunt
Anna Zygmunt
KKKarolina Karoń
Karolina Karoń
DPDaria Pedrycz
Daria Pedrycz
GDGrzegorz Drapała
Grzegorz Drapała
EPEmilia Pedrycz
Emilia Pedrycz
The Low-FODMAP diet has emerged as a key therapeutic intervention for managing irritable bowel syndrome (IBS), a prevalent gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits. This study aims to evaluate the efficacy of the Low-FODMAP diet in alleviating IBS symptoms and to explore its potential as a broader therapeutic tool in other gastrointestinal disorders, including inflammatory conditions. Our review highlights significant improvements in symptom relief, notably in reducing bloating, pain, and bowel irregularities, which are commonly associated with IBS. The Low-FODMAP diet’s mechanisms of action, involving modulation of gut microbiota and reduction of osmotic effects, provide new insights into its impact on gastrointestinal health.Our findings underscore the Low-FODMAP diet’s potential applications beyond IBS, suggesting benefits in conditions such as inflammatory bowel disease (IBD) and small intestinal bacterial overgrowth (SIBO). However, the long-term impacts of this diet on gut microbiota composition, mental health, and immune function require further investigation. Future research should focus on these aspects, especially in relation to diet sustainability and microbial diversity. The clinical implications of this study encourage healthcare providers to consider the Low-FODMAP diet as a personalized, non-pharmacological option for gastrointestinal symptom management, with careful monitoring to ensure nutritional adequacy and individual patient needs.

6 April 2025 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
AZAnna Ewa Zygmunt
Anna Ewa Zygmunt
MDMateusz Drabczyk
Mateusz Drabczyk
KKKarolina Karoń
Karolina Karoń
ŁKŁukasz Mikołaj Karoń
Łukasz Mikołaj Karoń
WGWojciech Krzysztof Grabowski
Wojciech Krzysztof Grabowski
SKSławomir Karoń
Sławomir Karoń
The gut microbiota, a complex ecosystem of microorganisms within the gastrointestinal tract, has emerged as a critical regulator of metabolic health. This review explores the intricate relationship between gut microbiota and insulin resistance, focusing on the underlying mechanisms, compositional changes, and therapeutic implications. Dysbiosis, characterized by reduced microbial diversity and an imbalance between beneficial and pathogenic species, contributes to insulin resistance through impaired short-chain fatty acid (SCFA) production, gut barrier dysfunction, and systemic inflammation. Key bacterial taxa, such as Akkermansia muciniphila and Faecalibacterium prausnitzii, play pivotal roles in maintaining metabolic homeostasis, while alterations in the Firmicutes-to-Bacteroidetes ratio and increased endotoxin production exacerbate metabolic dysfunction. Evidence suggests that modifiable factors, including diet, physical activity, and microbiota-targeted therapies like probiotics, prebiotics, and fecal microbiota transplantation (FMT), offer potential avenues for restoring microbial balance and mitigating insulin resistance. Despite advancements, research in this field faces challenges, including methodological variability, interindividual microbiota differences, and a need for standardized clinical approaches. Future studies should focus on long-term, large-scale interventional trials, personalized microbiota-based interventions, and elucidation of the gut microbiota's molecular mechanisms. This review underscores the promising role of gut microbiota in managing insulin resistance and highlights opportunities for integrating microbiota-targeted strategies into clinical practice.